Literature DB >> 28011817

A mechanism for evasion of CTL immunity by altered O-glycosylation of HLA class I.

Mihoko Sutoh Yoneyama1, Yuki Tobisawa2, Shingo Hatakeyama2, Misaki Sato1, Kiyoshi Tone3, Yota Tatara4, Ikuko Kakizaki4, Tomihisa Funyu1, Minoru Fukuda5, Senji Hoshi6, Chikara Ohyama2, Shigeru Tsuboi1,2.   

Abstract

Anti-tumour immunity by cytotoxic T-lymphocytes (CTLs) is essential to suppress tumour progression. Cancer cells that evade CTL immunity proliferate in the host, promoting metastasis, but mechanisms underlying this capacity remain unknown. Here we report that bladder cancer cells metastasized to lymph nodes evade CTL immunity by a new mechanism via altered glycosylation. CTLs normally recognize and kill cancer cells presenting antigenic peptides on human leukocyte antigen (HLA) class I. We show bladder cancer cells expressing the O-glycan processing enzyme, core2 β-1,6-N-acetylglucosaminyltransferase (C2GnT) exhibit HLA class I O-glycan modified with poly-N-acetyllactosamine and are highly susceptible to CTL. In those cells, poly-N-acetyllactosamine on HLA class I O-glycan binds galectin-3 to form a cell-surface molecular lattice, enabling efficient cell-surface retention of HLA class I. In contrast, bladder cancer cells in which C2GnT is downregulated show decreased levels of poly-N-acetyllactosamine on HLA class I O-glycans, attenuating lattice formation and reducing the cell-surface half-life of HLA class I. These tumour cells present antigenic peptides less efficiently, thereby evading CTL lysis and facilitating metastasis.
© The Authors 2017. Published by Oxford University Press on behalf of the Japanese Biochemical Society. All rights reserved.

Entities:  

Keywords:  O-glycan; cancer immunology; cytotoxic T-lymphocyte (CTL); galectin; immune evasion

Mesh:

Substances:

Year:  2017        PMID: 28011817     DOI: 10.1093/jb/mvw096

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  6 in total

Review 1.  How galectins have become multifunctional proteins.

Authors:  Gabriel García Caballero; Herbert Kaltner; Tanja J Kutzner; Anna-Kristin Ludwig; Joachim C Manning; Sebastian Schmidt; Fred Sinowatz; Hans-Joachim Gabius
Journal:  Histol Histopathol       Date:  2020-01-10       Impact factor: 2.303

Review 2.  The Roles of Glycans in Bladder Cancer.

Authors:  Yuli Jian; Zhongyang Xu; Chunyan Xu; Lin Zhang; Xiaoxin Sun; Deyong Yang; Shujing Wang
Journal:  Front Oncol       Date:  2020-06-12       Impact factor: 6.244

Review 3.  Research progress on O-GlcNAcylation in the occurrence, development, and treatment of colorectal cancer.

Authors:  Yao Liu; Fang-Xing Peng
Journal:  World J Gastrointest Surg       Date:  2021-02-27

4.  Core 2 β1,6-N-acetylglucosaminyltransferases accelerate the escape of choriocarcinoma from natural killer cell immunity.

Authors:  Kenichi Nakamura; Kaoru Niimi; Eiko Yamamoto; Yoshiki Ikeda; Kimihiro Nishino; Shiro Suzuki; Hiroaki Kajiyama; Fumitaka Kikkawa
Journal:  Biochem Biophys Rep       Date:  2021-02-13

5.  Tumor vasculature-targeted 10B delivery by an Annexin A1-binding peptide boosts effects of boron neutron capture therapy.

Authors:  Tohru Yoneyama; Shingo Hatakeyama; Mihoko Sutoh Yoneyama; Taku Yoshiya; Tsuyoshi Uemura; Takehiro Ishizu; Minoru Suzuki; Shingo Hachinohe; Shintaro Ishiyama; Motohiro Nonaka; Michiko N Fukuda; Chikara Ohyama
Journal:  BMC Cancer       Date:  2021-01-15       Impact factor: 4.430

Review 6.  Four Faces of Cell-Surface HLA Class-I: Their Antigenic and Immunogenic Divergence Generating Novel Targets for Vaccines.

Authors:  Mepur H Ravindranath; Narendranath M Ravindranath; Senthamil R Selvan; Edward J Filippone; Carly J Amato-Menker; Fatiha El Hilali
Journal:  Vaccines (Basel)       Date:  2022-02-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.